Effect of Tenapanor on the Metagenomics and Metabolomics of Patients With Irritable Bowel Syndrome With Constipation

PHASE4Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 6, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions

IBSIBS - Irritable Bowel Syndrome

Interventions

DRUG

Tenapanor

IBS-C patients will ingest one capsule of tenapanor (50 mg per dose), twice daily, before breakfast and dinner for a total of 8 weeks

Trial Locations (1)

Massachusetts General Hospital, Boston